These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15842653)

  • 21. Essential thrombocythemia and pregnancy.
    Valera MC; Parant O; Vayssiere C; Arnal JF; Payrastre B
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):141-7. PubMed ID: 21640467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy.
    Griesshammer M; Sadjadian P; Wille K
    Expert Rev Hematol; 2018 Sep; 11(9):697-706. PubMed ID: 30084669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronic myeloproliferative diseases. New knowledge about well known diseases].
    Aulitzky WE; Griesshammer M; Heimpel H; Huhn D
    Dtsch Med Wochenschr; 1996 May; 121(18):600-4. PubMed ID: 8625788
    [No Abstract]   [Full Text] [Related]  

  • 25. [Myeloproliferative syndrome].
    Nowotny P; Preussfner S; Konrad H; Engelmann C; Günther I
    Z Gesamte Inn Med; 1976 Apr; 31(8):250-4. PubMed ID: 986731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloproliferative disorders.
    Bench AJ; Cross NC; Huntly BJ; Nacheva EP; Green AR
    Best Pract Res Clin Haematol; 2001 Sep; 14(3):531-51. PubMed ID: 11640868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent progress in the treatment of hematological malignancies. IV. Therapy of myeloproliferative syndrome].
    Shibata A
    Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):796-801. PubMed ID: 2794661
    [No Abstract]   [Full Text] [Related]  

  • 31. The myeloproliferative disorders.
    Gilbert HS; Dameshek W
    Dis Mon; 1970 Oct; ():1-52. PubMed ID: 4921953
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of the myeloproliferative disorders : distinguishing data from dogma.
    Green AR; Vassiliou GS; Curtin N; Campbell PJ
    Hematol J; 2004; 5 Suppl 3():S126-32. PubMed ID: 15190294
    [No Abstract]   [Full Text] [Related]  

  • 33. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
    Kutti J; Ridell B
    Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Essential thrombocythemia.
    Finazzi G; Harrison C
    Semin Hematol; 2005 Oct; 42(4):230-8. PubMed ID: 16210036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?
    Hasselbalch HC; Riley CH
    Leuk Res; 2006 Oct; 30(10):1217-25. PubMed ID: 16483650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polycythemia rubra vera and pregnancy.
    Ferguson JE; Ueland K; Aronson WJ
    Obstet Gynecol; 1983 Sep; 62(3 Suppl):16s-20s. PubMed ID: 6877702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycythemia vera and pregnancy: experience of four pregnancies in a single patient.
    Aggarwal N; Chopra S; Suri V; Sikka P; Goundan A; Malhotra P
    Arch Gynecol Obstet; 2011 Feb; 283(2):393-5. PubMed ID: 20358212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.